FIELD: microbiology, vaccines. SUBSTANCE: invention relates to the live salmonellosis vaccine and novel live salmonellosis vaccines no used early. Invention relates to the use of live attenuated immunogenic vaccine strains of salmonellae Salmonella typhimurium Ssq/Sm 60/Rif 42 No. 4242 (deposition No. DSM 8433), Salmonella typhimurium Nal 2/Rif 9/Rtt 42 No. 4223 (deposition No. DSM 8432), Salmonella enteritidis Ssq/Sm 24/Rif 12 No. 4266 (deposition No. DSM 8435), Salmonella enteriditis Ssq/Sm 24/Rif 12K No. 4298 (deposition No. DSM 9362), Salmonella enteritidis Ssq/Sm 24/Rif 12g No. 4297 (deposition No. DSM 9361), Salmonells enteritidis Ssq/Sm 24/Rif 3 No. 4296 (deposition No. DSM 9360), Salmonella infantis Ssq/Sm 153/Rif 7 No. 4289 (deposition No. DSM 8434), Salmonella anatum Ssq/Sm 81/Rif 21 No. 4279 (deposition No. DSM 8441) containing a marker conferring sensitivity to macrolide antibiotics (envelope marker) for preparing the live vaccine for chickens. Vaccine is specific to definite host species and in the case of development of infectious process in another host as a result of contact with specific host it provides the possibility of carrying out effective therapeutic measures using macrolides. EFFECT: enhanced effectiveness of salmonellosis vaccines. 16 cl, 1 dwg, 4 tbl, 12 ex
